see also separate profiles for doravirine, lamivudine and tenofovir disoproxil
- Trade Name: Delstrigo (Merck Sharpe & Dohme)
- Indications: indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history.
- Half-life: 15 hours (doravirine); 5–7 hours (lamivudine); 17 hours (tenofovir disoproxil)
- FDA Approval Date: 08/30/2018
- Clinically important, potentially hazardous interactions with:
Carbamazepine, Enzalutamide, Ledipasvir & Sofosbuvir, Mitotane, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Sofosbuvir & Velpatasvir, St John's Wort - Pregnancy: insufficient data to adequately assess risk
POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
